Authors:
ANTHONY MT
ZEIGLER ZR
LISTER J
RAYMOND JM
SHADDUCK RK
KRAMER RE
GRYN JF
RINTELS PB
BESA EC
GEORGE JN
SILVER B
JOYCE R
BODENSTEINER D
Citation: Mt. Anthony et al., PLASMINOGEN-ACTIVATOR INHIBITOR (PAI-1) ANTIGEN LEVELS IN PRIMARY TTPAND SECONDARY TTP POST-BONE MARROW TRANSPLANTATION, American journal of hematology, 59(1), 1998, pp. 9-14
Citation: Ec. Besa et al., A PILOT TRIAL OF 13-CIS-RETINOIC ACID AND ALPHA-TOCOPHEROL WITH RECOMBINANT-HUMAN-ERYTHROPOIETIN IN MYELODYSPLASTIC SYNDROME PATIENTS WITH PROGRESSIVE OR TRANSFUSION-DEPENDENT ANEMIAS, Leukemia research, 22(8), 1998, pp. 741-749
Citation: Ec. Besa, IS MINIMAL RESIDUAL DISEASE IN THE PERIPHERAL-BLOOD STEM-CELL TRANSPLANTATION OF CHRONIC MYELOGENOUS LEUKEMIA IMPORTANT, Journal of clinical oncology, 15(9), 1997, pp. 3166-3166
Citation: A. Beedassy et al., THE PRESENCE OF BONE-MARROW FIBROSIS IN PRIMARY MYELODYSPLASTIC SYNDROMES IS NOT AN INDEPENDENT PREDICTOR OF SURVIVAL, Blood, 90(10), 1997, pp. 4028-4028
Citation: Ec. Besa et al., A COMBINATION OF IDARUBICIN, FLUDARABINE, ARA-C AND G-CSF INDUCTION WITH OR WITHOUT CONSOLIDATION USING BUSULFAN AND CYTOXAN (BU CY) PLUS PERIPHERAL-BLOOD STEM-CELL TRANSPLANTATION IN PATIENTS WITH POOR-PROGNOSIS MYELODYSPLASTIC SYNDROME (MDS) AND ACUTE MYELOGENOUS LEUKEMIA/, Blood, 90(10), 1997, pp. 4029-4029
Authors:
BESA EC
RUBIN S
CANOVA A
CAPUTO C
CONNOLLY MM
PIANTEDOSI R
BLANER W
Citation: Ec. Besa et al., A NOVEL RETINOID IN BONE-MARROW AND PLASMA FROM CONTROL SUBJECTS AND MYELODYSPLASTIC SYNDROME PATIENTS, Blood, 90(10), 1997, pp. 4030-4030
Authors:
ZEIGLER ZR
ROSENFELD CS
ANDREWS DF
NEMUNAITIS J
RAYMOND JM
SHADDUCK RK
KRAMER RE
GRYN JF
RINTELS PB
BESA EC
GEORGE JN
Citation: Zr. Zeigler et al., PLASMA VON-WILLEBRAND-FACTOR ANTIGEN (VWF-AG) AND THROMBOMODULIN (TM)LEVELS IN ADULT THROMBOTIC THROMBOCYTOPENIC PURPURA HEMOLYTIC-UREMIC SYNDROMES (TTP HUS) AND BONE-MARROW TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (BMT-TM)/, American journal of hematology, 53(4), 1996, pp. 213-220
Authors:
BESA EC
CANOVA A
ROSENFELD C
CONNOLLY MM
PIANTODOSI R
BLANER W
Citation: Ec. Besa et al., BONE-MARROW (BM) AND PLASMA-LEVELS OF ALL-TRANS-RETINOIC ACID (ATRA) IN NORMAL AND MYELODYSPLASTIC SYNDROME (MDS) PATIENTS, Blood, 88(10), 1996, pp. 2327-2327
Authors:
MOORE JS
FRIEDMAN DF
SILBERSTEIN LE
BESA EC
NOWELL PC
Citation: Js. Moore et al., CLINICAL HETEROGENEITY REFLECTS BIOLOGIC DIVERSITY IN CHRONIC LYMPHOCYTIC-LEUKEMIA, Critical reviews in oncology/hematology, 20(1-2), 1995, pp. 141-164
Authors:
BESA EC
TROTTMAN J
KLEASE C
BREHM P
ROVITO M
Citation: Ec. Besa et al., A COMBINATION OF IDARUBICIN, FLUDARABINE, ARA-C AND G-CSF (IFLAG) INDUCTION FOLLOWED BY HIGH-DOSE BUSULFAN CYTOXAN AND PERIPHERAL-BLOOD STEM-CELL RESCUE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME IN TRANSFORMATION AND POOR-PROGNOSIS ACUTE MYELOGENOUS LEUKEMIA (AML)/, Blood, 86(10), 1995, pp. 3148-3148
Authors:
NATHAN FE
HERMAN JH
KEASHENSCHNELL M
MCFARLAND JG
BESA EC
HADLEY C
CATALANO PM
Citation: Fe. Nathan et al., ANTI-BAKA NEONATAL ALLOIMMUNE THROMBOCYTOPENIA - POSSIBLE PREVENTION BY INTRAVENOUS IMMUNOGLOBULIN, Pediatric hematology and oncology, 11(3), 1994, pp. 325-329
Authors:
NOWELL PC
MOORE JS
FOX FE
CAPOCASALE RJ
KANT JA
BESA EC
Citation: Pc. Nowell et al., RICHTERS-SYNDROME ASSOCIATED WITH LOSS OF RESPONSE TO TRANSFORMING GROWTH-FACTOR-BETA, Leukemia research, 18(2), 1994, pp. 85-89
Citation: Ec. Besa, HEMATOLOGIC EFFECTS OF ANDROGENS REVISITED - AN ALTERNATIVE THERAPY IN VARIOUS HEMATOLOGIC CONDITIONS, Seminars in hematology, 31(2), 1994, pp. 134-145
Citation: Ec. Besa et al., CYTOGENETIC AND MOLECULAR REMISSIONS IN PATIENTS WITH STABLE PHASE CHRONIC MYELOGENOUS LEUKEMIA TREATED WITH LONG-TERM INTERFERON-ALPHA, Blood, 84(10), 1994, pp. 10000155-10000155
Citation: Ec. Besa et al., RANDOMIZED CLINICAL-TRIAL OF 13-CIS RETINOIC ACID WITH OR WITHOUT RECOMBINANT-HUMAN-ERYTHROPOIETIN IN MYELODYSPLASTIC SYNDROME PATIENTS WITH PROGRESSIVE OR TRANSFUSION-DEPENDENT ANEMIAS, Blood, 84(10), 1994, pp. 10000317-10000317
Authors:
ROVITO MA
LUCE M
NOWELL PC
SIEGEL JE
NEILAN BA
BESA EC
Citation: Ma. Rovito et al., MINIMAL RESIDUAL DISEASE-FREE COLLECTION OF PERIPHERAL-BLOOD STEM-CELLS IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA AFTER INTERFERON-ALPHA THERAPY, Blood, 84(10), 1994, pp. 10000351-10000351
Citation: Ma. Rovito et al., ERADICATION OF TRISOMY-8 BY I-FLAG THERAPY IN A PATIENT WITH MYELODYSPLASTIC SYNDROME RAEB CLASSIFICATION, Blood, 84(10), 1994, pp. 10000636-10000636
Citation: Ec. Besa et al., SUCCESSFUL TREATMENT OF A PANCYTOPENIC PATIENT WHO BECAME REFRACTORY TO RED-CELL AND PLATELET TRANSFUSIONS DUE TO ALLOIMMUNIZATION USING PROTEIN-A IMMUNOADSORPTION, Blood, 84(10), 1994, pp. 10000661-10000661
Authors:
MOORE JS
CAPOCASALE RJ
FOX FE
LAMB RJ
BESA EC
PENZINER AS
NOWELL PC
Citation: Js. Moore et al., RESPONSE OF CLL B-CELLS TO TRANSFORMING GROWTH-FACTOR-BETA REFLECTS BIOLOGICAL HETEROGENEITY, Blood, 82(10), 1993, pp. 10000573-10000573
Citation: Ma. Rovito et al., MINIMAL RESIDUAL DISEASE RESIDES IN BONE-MARROW BUT NOT PERIPHERAL-BLOOD STEM-CELLS OF A PATIENT WITH CHRONIC MYELOGENOUS LEUKEMIA IN COMPLETE CYTOGENETIC REMISSION AFTER INTERFERON-ALPHA THERAPY, Blood, 82(10), 1993, pp. 10000641-10000641